Valuation : Delcath Systems, Inc.

Market Cap 567M 489M 458M 418M 788M 54.19B 790M 5.43B 2.12B 27.35B 2.13B 2.08B 90.7B P/E 2026 *
-109x
P/E 2027 * -204x
Enterprise Value 567M 489M 458M 418M 788M 54.19B 790M 5.43B 2.12B 27.35B 2.13B 2.08B 90.7B EV / Sales 2026 *
5.34x
EV / Sales 2027 * 4.3x
Free-Float
91.92%
Yield 2026 *
-
Yield 2027 * -
1 day-0.31%
1 week-4.67%
Current month+33.72%
1 month+41.47%
3 months+49.22%
6 months+83.60%
Current year+61.78%
1 week 16.15
Extreme 16.15
17.14
1 month 11.63
Extreme 11.63
17.42
Current year 8.48
Extreme 8.485
17.42
1 year 8.12
Extreme 8.12
17.42
3 years 2.25
Extreme 2.25
18.23
5 years 2.25
Extreme 2.25
18.23
10 years 2.25
Extreme 2.25
525,609,756.1
Manager TitleAgeSince
Chief Executive Officer 62 2020-09-30
Director of Finance/CFO 47 2023-04-30
Chief Operating Officer 55 2024-03-17
Director TitleAgeSince
Chairman 62 2023-02-15
Director/Board Member 70 2020-02-13
Director/Board Member 60 2020-05-05
Date Insider Type Main position Quantity % Market Cap.
5/13/26 Free

Director

22,500 0.0646%
5/13/26 Free

Director

22,500 0.0646%
5/13/26 Free

Director

22,500 0.0646%
Change 5-day change 1-year change 3-year change Capi.($)
-0.31%-4.67%+50.18%+228.11% 569M
+1.11%+0.41%-1.52%-30.11% 18.29B
-1.01%-4.01%+1.43%-0.04% 17.5B
-1.20%+0.46%-54.66%-48.90% 6.48B
+1.35%+0.67% - - 4.42B
-0.34%-2.00%-9.26%-4.23% 1.96B
+1.08%-2.59%+28.15%+54.54% 1.91B
-0.02%-0.86%-49.95%-52.53% 1.16B
-2.21%-0.24%+54.14%+177.97% 999M
-2.64%-6.48% - - 303M
Average -0.42%-1.36%+2.31%+40.60% 5.36B
Weighted average by Cap. -0.02%-2.20%-6.07%-10.76%

Financials

2026 *2027 *
Net sales 106M 91.52M 85.81M 78.33M 148M 10.15B 148M 1.02B 397M 5.12B 399M 390M 16.99B 132M 114M 107M 97.34M 183M 12.61B 184M 1.27B 494M 6.37B 496M 485M 21.11B
Net income -5.72M -4.93M -4.62M -4.22M -7.95M -547M -7.97M -54.84M -21.4M -276M -21.48M -21.01M -915M -3.39M -2.92M -2.74M -2.5M -4.71M -324M -4.72M -32.48M -12.67M -163M -12.72M -12.44M -542M
Net Debt - -
Logo Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. The Company's proprietary products, HEPZATO KIT (HEPZATO (melphalan) for Injection/Hepatic Delivery System) and CHEMOSAT Hepatic Delivery System for Melphalan percutaneous hepatic perfusion (PHP), are designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects during a PHP procedure. HEPZATOTM KIT is a drug/device combination product. HEPZATO KIT comprises the chemotherapeutic drug melphalan and the Company’s proprietary Hepatic Delivery System (HDS). In Europe, the device-only configuration of the HDS is regulated as a Class III medical device and is approved for sale under the trade name CHEMOSAT Hepatic Delivery System for Melphalan. In the United States, HEPZATO is regulated as a drug by the United States Food and Drug Administration (FDA).
Employees
156
Date Price Change Volume
26-08-28 US$16.34 -0.31% 491,047
26-08-27 US$16.39 -0.06% 402,571
26-08-26 US$16.40 -3.07% 367,176
26-08-25 US$16.92 +1.01% 503,723
26-08-24 US$16.75 -2.28% 417,051
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
16.34USD
Average target price
24.00USD
Spread / Average Target
+46.88%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. DCTH Stock